Evidence mapPaperPMID 42369237Full record

ArticleToxicology reports2026

Neuronal safety of Kv11.1 blockers: Patch-clamp and in vitro evaluation with physiologically based pharmacokinetic (PBPK) modeling.

Gül Öncü, Armağan Koçer, Hale Saybaşılı

Abstract read
In one paragraph

Article in Toxicology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gül ÖncüInstitute of Biomedical Engineering, Boğaziçi University, Istanbul, Turkiye.
Armağan KoçerDepartment of Bioelectric Signaling and Engineering, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands.
Hale SaybaşılıInstitute of Biomedical Engineering, Boğaziçi University, Istanbul, Turkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Class III antiarrhythmic drugs are indispensable for cardiac rhythm control, yet their susceptibility to clinically used ion channel modulating drugs remains insufficiently characterized. Because Kv11.1 channels are present in neurons and glia, their pharmacological engagement may influence excitability and cell viability. Here, we investigated Sotalol, Ibutilide, and Amiodarone, three clinically used Kv11.1 active compounds with distinct lipophilicity profiles, using an integrated strategy that combines whole-cell patch-clamp electrophysiology, cell viability assays, and physiologically based pharmacokinetic (PBPK) modeling in neuron-like SH-SY5Y cells, a human model widely used for neurotoxicity and ion-channel studies. Sotalol produced minimal electrophysiological changes, whereas Ibutilide caused moderate suppression of outward K⁺ currents, and Amiodarone did not show acute effects under our patch-clamp conditions. However, Amiodarone induced pronounced morphological changes and loss of viability

Indexed as

BBB permeabilityClass III antiarrhythmicsNeuronal toxicityNeuron-like SH-SY5Y cellsPatch-clamp electrophysiologyPharmacokinetic modeling

Identifiers

PMID42369237
PMCPMC13308230

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.